EQ — Equillium, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1746466 ·
Last close
$2.20
Market Cap
$139.10M
52W High
$3.54
52W Low
$1.76
ADV30
824,637
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -5,610,000 | -5,311,000 | 63,083,000 | 61,322,000 | 3,596,000 |
| Dec 2025 | 0 | — | -3,962,000 | -3,775,000 | 31,887,000 | 30,277,000 | 3,290,000 |
| Sep 2025 | 0 | — | -4,575,000 | -4,230,000 | 34,506,000 | 33,120,000 | 3,567,000 |
| Jun 2025 | 0 | — | -6,228,000 | -5,739,000 | 12,399,000 | 11,495,000 | 7,343,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-18,878,000
Investing CF
$-35,000
Financing CF
$65,682,000
CapEx
$-55,000
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-0.32
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-221,516,000
Inventory
—
Receivables
$108,000
ST Investments
$0
EBIT TTM
$-20,375,000
Pretax Income TTM
$-19,055,000
Interest Exp TTM
$0
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -23,634,000 | -22,398,000 | 31,887,000 | 3,290,000 | — | -22,746,000 |
| Dec 2024 | 41,095,000 | -8,269,000 | -8,067,000 | 25,604,000 | 6,543,000 | — | -19,026,000 |
| Dec 2023 | 36,084,000 | -14,522,000 | -13,335,000 | 50,530,000 | 27,957,000 | — | -21,783,000 |
| Dec 2022 | 15,759,000 | -39,027,000 | -62,428,000 | 78,421,000 | 46,479,000 | — | -8,733,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.27
Max Pain — expiry 2026-10-16
max pain strike: $2.50 · spot: $2.20 · call oi: 294 · put oi: 2,408
Expected Move to 2026-10-16:
±$0.55
(25.00%) —
implied range
$1.65 –
$2.75
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MIST | Milestone Pharmaceuticals Inc. | $138.19M | $1.11 | — |
| HURA | TuHURA Biosciences, Inc./NV | $138.19M | $2.17 | — |
| UNCY | Unicycive Therapeutics, Inc. | $137.24M | $5.01 | — |
| DERM | Journey Medical Corp | $137.18M | $6.37 | — |
| NRXP | NRX Pharmaceuticals, Inc. | $134.82M | $3.15 | — |
News headlines (Yahoo Finance, 1h cache)
Analysts Grow More Confident In Equillium’s (EQ) Lead Asset EQ504
2026-06-10 17:45 · Yahoo
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-06-02 20:05 · Yahoo
Equillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 1
2026-05-29 15:03 · Yahoo
Equillium to Host Virtual Investor Event to Share New Insights into the Aryl Hydrocarbon Receptor (AhR) and miR-124 Axis
2026-05-20 20:05 · Yahoo
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights
2026-05-13 20:01 · Yahoo
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event
2026-04-20 20:05 · Yahoo
Equillium Announces Poster Presentations at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists
2026-04-08 12:30 · Yahoo
Equillium Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate and Clinical Highlights
2026-03-25 20:05 · Yahoo
Here’s What Roth Capital Thinks of Equillium (EQ) Stock
2026-03-24 21:38 · Yahoo
Equillium to Participate in the 38th Annual Roth Conference
2026-03-18 12:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.